Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease

Journal of Nuclear Medicine

Volumn 37, Issue 3, 1996, Pages 421-426

  Vingerhoets, François J G ^b   Schulzer, Michael ^b   Ruth, Thomas J ^b   Holden, James E ^b   Snow, Barry J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

Fluorodopa; Parkinson's disease; PET

Indexed keywords

DOPAMINE; FLUORINE 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030002979     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. CAPIT Committee. Core assessment program for intracerebral transplantations (CAPIT) In: Lindvall O, Bjorklund A, Widner H, eds. Intracerebral transplantation in movement disorders. Amsterdam: Elsevier, 1991:227-241.
2. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomography studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764
3. Bhatt M, Snow BJ, Martin WRW, Pate BD, Ruth TJ, Calne DB. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991,29:673-677.
4. Laihinen A, Rinne JO, Rinne UK, et al. Fluorine-18-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 1992;42:199-203.
5. Holden JE, Pate BD, Snow BJ, et al. Effects of simultaneous inhibition of MAO-B and COMT on striatal L-6-fluorodopa kinetics in nonhuman primates [Abstract]. Sixth symposium on the medical application of cyclotrons. Turku, Finland: 1992.
6. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implication for levodopa therapy in Parkinson's disease Neurology 1994,44:1292-1297.
7. Guttman M, Burns RS, Martin WRW, et al. PET studies of parkinsonian patients treated with autologous adrenal transplants. Can J Neurol Sci 1989,16:305-309.
8. 18F]-6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992;31:166-173.
9. Widner H, Tetrud JW, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992;327:1556-1563.
10. van Belle G, Uhlmann RF, Hughes JP, Larson EB. Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type J Clin Epidemiol 1990,43.589-595.
11. Pate BD, Snow BJ, Hewitt KA, Morrison KS, Ruth TJ, Calne DB. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18 L-6-fluorodopa tracer in nonhuman primates. J Nucl Med 1991,32:1246-1251.
12. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-23
13. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127
14. Hoehn MM, Yahr MD Parkinsonism: onset, progression and mortality Neurology 1967;5:427-442.
15. 18F]6-fluorodopa. Int J Appl Radiat Isot 1988;39:1203-1206
16. 18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci 1992;50:309-318.
17. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in human studied with positron emission tomography. Ann Neurol 1989;26 535-542.
18. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 1985;5: 584-590
19. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
20. 18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography Acta Neurol Scand 1990;81:24-30.
21. Brooks DJ, Salmon E, Mathias CJ. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease studied with PET. Brain 1990,113:1539-1552.
22. 18F]fluoro-L-DOPA metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 1993;13:57-69.
23. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism m patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatr 1986;49:853-860.
24. Scheffé H. The analysis of variance. New York: Wiley; 1959:221-260.
25. 18F]6-fluorodopa input function: a simplified method. J Cereb Blood Flow Metab 1992;12:881-884.
26. 18F-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986;39:2243-2252.
27. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988,318:876-880.
28. 18F]-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
29. Carson RE. Precision and accuracy considerations of physiological quantitation in PET. J Cereb Blood Flow Metab 1991;11:A45-A50.
30. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994;35.955-963.
31. Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F-18 positron emission tomography data. Arch Neurol 1994;51:237-243.
32. Powers WJ, Berg L, Perlmutter JS, Raichle ME. Technology assessment revisited: does positron emission tomography have proven clinical efficacy? Neurology 1991; 41:1339-1340.
33. Therapeutics and Technology Assessment Subcommittee. Assessment: positron emission tomography. Neurology 1991;41:163-167.
34. 18F-dopa PET data J Neurol Neurosurg Psychiatry 1994,57:278-284.
35. Vingerhoets FJG, Snow BJ, Tetrud JW, Langsten JW, Schulzer M, Calne DB. Positron tomography evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994,36 765-770.